Sign In
Buy TGTX
$40.11
+3.47 (+9.47%)
At Close: Jun 03, 2026
NanoString Technologies (NSTG) Reports Q2 Loss, Lags Revenue Estimates
09:35pm, Thursday, 04'th Aug 2022 Zacks Investment Research
NanoString (NSTG) delivered earnings and revenue surprises of -37.10% and 0.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Boston Scientific (BSX) Tops Q2 Earnings and Revenue Estimates
11:45am, Wednesday, 27'th Jul 2022 Zacks Investment Research
Boston Scientific (BSX) delivered earnings and revenue surprises of 4.76% and 0.92%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
TG Therapeutics And Ublituximab: From Icing To Lifeline
10:51am, Friday, 08'th Jul 2022
Ublituximab used to be TGTX's second asset and a very large potential icing on the cake for the company. After umbralisib went down, ubli has become its lifeline.
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 8Th Congress of the European Academy of Neurology
11:30am, Monday, 27'th Jun 2022 GlobeNewswire Inc.
NEW YORK, June 27, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data presentations highlighting data from pooled and post hoc analyses of the ULTIMATE I & II Phas
Valneva SE Sponsored ADR (VALN) Stock Jumps 93.1%: Will It Continue to Soar?
11:43am, Wednesday, 22'nd Jun 2022 Zacks Investment Research
Valneva SE Sponsored ADR (VALN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further p
TG Therapeutics (TGTX) Soars 18.7%: Is Further Upside Left in the Stock?
01:20pm, Thursday, 09'th Jun 2022 Zacks Investment Research
TG Therapeutics (TGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
TG Therapeutics (TGTX) Soars 18.7%: Is Further Upside Left in the Stock?
10:32am, Thursday, 09'th Jun 2022
TG Therapeutics (TGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
NEW YORK, June 03, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data presentations, including one oral and two poster presentations, highlighting data from explor
FDA Delays Decision on TGTX's BLA for Multiple Sclerosis Drug
06:22pm, Wednesday, 01'st Jun 2022 Zacks Investment Research
The FDA extends PDUFA date by three months on TG Therapeutics' (TGTX) regulatory submission for ublituximab for relapsing multiple sclerosis. Shares fell 14.5% following the announcement.
FDA Delays Decision on TGTX's BLA for Multiple Sclerosis Drug
03:48pm, Wednesday, 01'st Jun 2022
The FDA extends PDUFA date by three months on TG Therapeutics' (TGTX) regulatory submission for ublituximab for relapsing multiple sclerosis. Shares fell 14.5% following the announcement.
TG Therapeutics Announces FDA Extension of BLA PDUFA Date for Ublituximab to Treat Patients with RMS
11:30am, Tuesday, 31'st May 2022 GlobeNewswire Inc.
New PDUFA goal date of December 28, 2022 New PDUFA goal date of December 28, 2022
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting
11:30am, Thursday, 26'th May 2022 GlobeNewswire Inc.
NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations, including one oral and two poster presentations, highlighting d
Time to Weed Your Holdings and Upgrade Your Portfolio
10:49am, Monday, 23'rd May 2022
With the stock market down 18% from its peak as of May 20, now is a good time for a portfolio upgrade.
Benzinga's Top Ratings Upgrades, Downgrades For May 20, 2022
02:02pm, Friday, 20'th May 2022 Benzinga
Upgrades
For Telia Company AB (OTC:TLSNY), UBS upgraded the previous rating of Neutral to Buy. For the first quarter, Telia Company had an EPS of $0.05, compared to year-ago quarter EPS of $0.03. The
What 4 Analyst Ratings Have To Say About TG Therapeutics
12:30pm, Friday, 20'th May 2022 Benzinga
Over the past 3 months, 4 analysts have published their opinion on TG Therapeutics (NASDAQ:TGTX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a
